Anti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/Nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients

Anti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/Nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 28; p. v268
Main Authors: Carrier, E., Picozzi, V., Pishvaian, M.J., Mody, K., Winter, J., Glaspy, J., Larson, T., Conway, W.C., Lipson, K., Porter, S., Kouchakji, E.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-09-2017
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdx369.166